TWI262805B - Pharmaceutical composition for treating or inhibiting colonic polyps - Google Patents

Pharmaceutical composition for treating or inhibiting colonic polyps

Info

Publication number
TWI262805B
TWI262805B TW090105702A TW90105702A TWI262805B TW I262805 B TWI262805 B TW I262805B TW 090105702 A TW090105702 A TW 090105702A TW 90105702 A TW90105702 A TW 90105702A TW I262805 B TWI262805 B TW I262805B
Authority
TW
Taiwan
Prior art keywords
treating
pharmaceutical composition
colonic polyps
inhibiting colonic
inhibiting
Prior art date
Application number
TW090105702A
Other languages
English (en)
Inventor
Philip Frost
Carolyn M Discafani-Marro
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of TWI262805B publication Critical patent/TWI262805B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW090105702A 2000-03-13 2001-03-12 Pharmaceutical composition for treating or inhibiting colonic polyps TWI262805B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52419600A 2000-03-13 2000-03-13

Publications (1)

Publication Number Publication Date
TWI262805B true TWI262805B (en) 2006-10-01

Family

ID=24088181

Family Applications (1)

Application Number Title Priority Date Filing Date
TW090105702A TWI262805B (en) 2000-03-13 2001-03-12 Pharmaceutical composition for treating or inhibiting colonic polyps

Country Status (23)

Country Link
EP (1) EP1263503B1 (zh)
JP (1) JP2003526686A (zh)
KR (2) KR100817423B1 (zh)
CN (1) CN1190197C (zh)
AR (1) AR035482A1 (zh)
AT (1) ATE308364T1 (zh)
AU (2) AU2001245452B2 (zh)
BR (1) BR0109165A (zh)
CA (1) CA2402742C (zh)
DE (1) DE60114580T2 (zh)
DK (1) DK1263503T3 (zh)
EA (1) EA200200976A1 (zh)
ES (1) ES2248302T3 (zh)
HK (1) HK1048775B (zh)
HU (1) HUP0300547A2 (zh)
IL (2) IL151249A0 (zh)
MX (1) MXPA02008836A (zh)
NO (1) NO20024356L (zh)
NZ (1) NZ521117A (zh)
PL (1) PL202873B1 (zh)
TW (1) TWI262805B (zh)
WO (1) WO2001068186A2 (zh)
ZA (1) ZA200208178B (zh)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
JP2005519876A (ja) 2001-11-27 2005-07-07 メルク　エンド　カムパニー　インコーポレーテッド ２−アミノキノリン化合物
DE60328461D1 (de) * 2002-01-28 2009-09-03 Ube Industries Verfahren zur herstellung eines chinazolin-4-onderivats
EP1472213B1 (en) * 2002-02-05 2010-06-09 Wyeth a Corporation of the State of Delaware Process for the synthesis of n-acyl-2-amino-4-alkoxy-5-nitrobenzoic acids
US7009053B2 (en) * 2002-04-30 2006-03-07 Yungjin Pharmaceuticals Co., Ltd. Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
DE10221018A1 (de) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
ES2338545T3 (es) 2002-12-20 2010-05-10 Pfizer Products Inc. Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
CA2537812C (en) 2003-09-26 2013-01-22 Exelixis, Inc. C-met modulators and method of use
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
EP1758887A1 (en) 2004-05-14 2007-03-07 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
EP1756090A1 (en) 2004-05-14 2007-02-28 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005111022A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidines derivatives for the treatment of abnormal cell growth
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
EP1883630A2 (en) * 2005-05-25 2008-02-06 Wyeth Methods of synthesizing 6-alkylaminoquinoline derivatives
CA2629244C (en) 2005-11-11 2014-08-05 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
DE102006029445A1 (de) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Neue 3-Cyano-chinoline als Kinase-Inhibitoren
DE102006029446A1 (de) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Neue 3-substituierte-Chinoline als Kinase-Inhibitoren
WO2008034776A1 (en) 2006-09-18 2008-03-27 Boehringer Ingelheim International Gmbh Method for treating cancer harboring egfr mutations
DE102007024470A1 (de) 2007-05-24 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Neue Sulfoximin-substituierte Chinolin- bzw. Chinazolinderivate als Kinase-Inhibitoren
EP2072502A1 (de) 2007-12-20 2009-06-24 Bayer Schering Pharma Aktiengesellschaft Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren
CA2995880C (en) 2009-01-16 2021-01-05 Exelixis, Inc. Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
MX2011013666A (es) 2009-06-25 2012-03-06 Amgen Inc Compuestos heterociclicos y sus usos.
ES2731901T3 (es) 2009-07-06 2019-11-19 Boehringer Ingelheim Int Proceso para el secado de BIBW2992, de sus sales y de formulaciones farmacéuticas sólidas que comprenden este ingrediente activo
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
JP6533997B2 (ja) * 2014-12-26 2019-06-26 株式会社ヤクルト本社 Ｚｎｆ１４３阻害活性を有する化合物およびその利用
EP3280708B1 (en) * 2015-04-10 2021-09-01 Araxes Pharma LLC Substituted quinazoline compounds and methods of use thereof
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058805A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
CA3005089A1 (en) 2015-11-16 2017-05-26 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
EP3573970A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573967A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused hetero-hetero bicyclic compounds and methods of use thereof
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
JP2020521741A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー がんの処置のための化合物およびその使用の方法
BR112019024674A2 (pt) 2017-05-25 2020-06-16 Araxes Pharma Llc Inibidores covalentes da kras
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
CZ2002474A3 (cs) * 1999-08-12 2003-02-12 American Cyanamid Company Prostředek pro léčení nebo inhibici polypů tlustého střeva a kolorektální rakoviny obsahující NSAID a inhibitor EGFR kinasy

Also Published As

Publication number Publication date
WO2001068186A2 (en) 2001-09-20
HUP0300547A2 (hu) 2003-07-28
CA2402742C (en) 2009-05-12
EA200200976A1 (ru) 2003-02-27
DE60114580T2 (de) 2006-07-27
CA2402742A1 (en) 2001-09-20
ZA200208178B (en) 2004-02-11
AU2001245452B2 (en) 2005-05-05
AU4545201A (en) 2001-09-24
HK1048775B (zh) 2006-01-20
CN1429126A (zh) 2003-07-09
BR0109165A (pt) 2003-04-22
ATE308364T1 (de) 2005-11-15
JP2003526686A (ja) 2003-09-09
KR20020092987A (ko) 2002-12-12
CN1190197C (zh) 2005-02-23
ES2248302T3 (es) 2006-03-16
DE60114580D1 (de) 2005-12-08
DK1263503T3 (da) 2006-02-13
NZ521117A (en) 2005-02-25
WO2001068186A3 (en) 2002-01-17
KR20080009294A (ko) 2008-01-28
IL151249A0 (en) 2003-04-10
IL151249A (en) 2008-06-05
MXPA02008836A (es) 2003-02-10
NO20024356L (no) 2002-11-12
PL202873B1 (pl) 2009-07-31
KR100817423B1 (ko) 2008-03-27
AR035482A1 (es) 2004-06-02
EP1263503B1 (en) 2005-11-02
NO20024356D0 (no) 2002-09-12
HK1048775A1 (en) 2003-04-17
PL363072A1 (en) 2004-11-15
EP1263503A2 (en) 2002-12-11

Similar Documents

Publication Publication Date Title
TWI262805B (en) Pharmaceutical composition for treating or inhibiting colonic polyps
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
IL136044A (en) 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
MY133473A (en) Haterocyclic glycyl beta-alanine derivatives.
MXPA02012034A (es) Derivados de tiofeno utiles como agentes anticancerosos.
WO2003082205A3 (en) Compounds and methods
PL344861A1 (en) Trazinic angiogenesis inhibitiors
MXPA05012837A (es) Inhibidores de caspasa y usos de los mismos.
MXPA05009611A (es) Piperidinas sustituidas como nuevos inhibidores de mdm2-p53.
DE60112330D1 (en) Pyrazolopyridinderivate
HK1085675A1 (en) Anticancer compounds
AP2002002616A0 (en) Antidibetic agents
PL1682528T3 (pl) Pochodne benzo[b][1,4]dioksepiny
MXPA04006041A (es) Antivirales de piridoquinoxalina.
EE200000472A (et) Kasvajavastased toimeained
AU2003223340A8 (en) Certain pharmaceutically useful substituted aminoalkyl heterocycles
AP2002002387A0 (en) Method of inhibiting amyloid aggregation and imaging amyloid deposits.
IL157540A (en) Pharmaceutical compositions comprising n-(aryl)-2-arylethenesulfonamides, some such novel compounds and process for their preparation
WO2003080631A3 (en) Plasma carboxypeptidase b inhibitors
DE60135752D1 (en) Tyrosinderivate als phosphatase inhibitoren
AU2368802A (en) Use of substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence
WO2002098399A3 (en) Cancer treatment method and compositions comprising compounds of the ginger family
UA85994C2 (en) N, n'-substituted-1,3-diamino-2-hydroxypropane derivatives
ZA200400824B (en) Pyridin-2-yl-methlyamine derivatives for treating opioid dependence.